3D QSAR based study of potent growth inhibitors of terpenes as Antimycobacterial agents

Open Nutraceuticals Journal

Volumn 4, Issue , 2011, Pages 119-124

  Dwivedi, Neeraja ^a,b,c   Mishra, Sanjay ^b   Mishra, Bhartendu Nath ^a   Singh, R B ^d   Katoch, Vishwa Mohan ^c  

^a INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

^b IFTM Campus   (India)

^c INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^d HALBERG HOSPITAL AND RESEARCH INSTITUTE   (India)

Author keywords

CoMFA; MIC; Mycobacterium tuberculosis; QSAR; Terpene

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BETULIC ACID; BETULIN; BOMYL; CAMARIC ACID; DIAPORTHEIN A; DIAPORTHEIN B; EPIOLEANOLIC ACID; EPIURSOLIC ACID; ERGOG; HETERONEMIN; HOMOPSEUDO; LANTANOLIC ACID; LANTINILIC ACID; LECHERONOL A; LECHERONOL B; LITOSTEROL; NAPHALSTEROL; NATURAL PRODUCT; OLEANOLIC ACID; PHORBOL ESTER; PSEUDOPTERAZOLE; REHMANIC ACID; SARINGOSTEROL; TERPENE DERIVATIVE; TOTAROL; UNCLASSIFIED DRUG; URSOLIC ACID; BORNEOL; DITERPENE; NEPHALSTEROL; SESQUITERPENE; TERPENE; TRITERPENE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHEMICAL PARAMETERS; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG POTENCY; DRUG STRUCTURE; ELECTROSTATIC FIELD; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STERIC FIELD; BIODIVERSITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; STATIC ELECTRICITY; THREE DIMENSIONAL QUANTITATIVE STRUCTURE ACTIVITY RELATION;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79958150187     PISSN: None     EISSN: 18763960     Source Type: Journal    
DOI: 10.2174/1876396001104010119     Document Type: Article

References (25)

1. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005; 73/74: 17.
2. The Global Plan to Stop TB, 2006-2015. Document available from www.stoptb.org.
3. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000; 17: 215.
4. Economics of TB drug development. Report available from Global Alliance for TB Drug Development, www.tballiance.org.
5. Pauli GF, Case RJ, Inui T, et al. New perspectives on natural products in TB drug research. Life Sci 2005; 78: 485-94.
6. Economics of TB drug development. Report available from Global Alliance for TB Drug Development, www.tballiance.org
7. Web source: www.tballiance.org.
8. Cramer RD III, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA): Effect of shape on binding steroids to carrier proteins. J Am Chem Soc 1988; 110: 5959-67.
9. Talale TT, Kulkarni SS, Kulkarni VM. Development of pharmacophore alignment models as input for comparative molecular field analysis of a diverse set of azole antifungal agents. J Chem Inf Comput Sci 1999; 39: 958-66.
10. Murthy VS, Kulkarni VM. 3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem 2002; 10: 2267-82
11. Gohlke H, Klebe G. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledgebased pair-potentials to a particular protein. J Med Chem 2002; 45: 4153-70.
12. Cramer RD. Topomer CoMFA: a design methodology for rapid lead optimization. J Med Chem 2003; 46: 374-88.
13. Copp BR, Pearce AN. Natural product growth inhibitors of Mycobacterium tuberculosis. Nat Prod Rep 2007; 24: 278-97.
14. Hokuldsson A. PLS regression methods. J Chemometrics 1988; 2: 211-28.
15. Zhaoqi Y, Pinghua S. 3D-QSAR Study of Potent Inhibitors of Phosphodiesterase-4 Using a CoMFA Approach. Int J Mol Sci 2007; 8(7): 714-22.
16. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 2002; 8: 1255-96.
17. Xu M, Zhang AQ, Han SK, Wang LS. Studies of 3D-quantitative structure-activity relationships on a set of nitroaromatic compounds: CoMFA, advanced CoMFA and CoMSIA. Chemsphere 2002; 48: 707-15.
18. Woldemichael GM, Gutierrez-Lugo M-T, Franzblau SG, Wang Y, Suarez E, Timmermann BN. Mycobacterium tuberculosis growth inhibition by constituents of Sapium haematospermum. J Nat Prod 2004; 67: 598.
19. Gu J-Q, Wang Y, Franzblau SG, Montenegro G, Yang D, Timmermann BN. Antitubercular constituents of Valeriana laxiflora. Planta Med 2004; 70(6): 509-14.
20. Rodŕi{dotless}guez II, Rodŕi{dotless}guez AD. Homopseudopteroxazole, a new antimycobacterial diterpene alkaloid from Pseudopterogorgia elisabethae. J Nat Prod 2003; 66(6): 855-7.
21. Sayed KAE, Bartyzed P, Shen X, Zjawiony JK, Hamann MT. Marrine natural products as antituberculosis agents. Tetrahedron 2000; 56: 949-53.
22. Rukachaisirikul T, Prabpai S, Kongsaeree P, Suksamrarn A. (+)-Bornyl piperate, a new monoterpene ester from Piper aff. pedicellatum roots. Chem Pharm Bull 2004; 52(6): 760-1.
23. Chumkaew P, Karalai C, Ponglimanont C, Chantrapromma K. Antimycobacterial activity of phorbol esters from the fruits of Sapium indicum. J Nat Prod 2003; 66(4): 540-3.
24. Guchi KI, Saitoh S, Yamata Y. Novel 19-oxygenated Saitoh S, Yamata Y. Novel 19-oxygenated sterols from the okinawan soft coral Litophytom Viridis. Chem Pharm Bull 1989; 37: 2553-4.
25. Boruwa B, Kalita N, Barua JC, et al. Synthesis, Absolute Stereochemistry and Molecular Design of the New Antifungal and Antibacterial Antibiotic Produced by Streptomyces sp. Med Chem Lett 2004; 14: 3571.